Interestingly, clinical trials in patients with COPD have reported that cardiovascular events were reduced by the PDE4 pan-inhibitor roflumilast [79], supporting the interest in selective PDE4 inhibition for the treatment of cardiac disorders. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.